Macter International Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Public pharmaceutical manufacturer · Karachi · Pakistan
Publicly listed Pakistan pharmaceutical manufacturer with branded-generic, biotech and contract-manufacturing operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical manufacturer
- Address
- F-216, S.I.T.E., Karachi-75700, Pakistan · 75700
- Website
- macter.com ↗
- Phone
- +92 21 32575311-14
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Bacticlor | Cephalexin | 500 mg | Capsule | 12 | 073633 | PKR 426.56 | PKR 35.55/capsule | 16% above median |
| Benza L.A | Benzathine penicillin G | 0.6 MIU | Injection | 1's | 037769 | PKR 119.29 | PKR 119.29/vial/unit | No comparator |
| Benza L.A | Benzathine penicillin G | 1.2 MIU | Injection | 1's | 037770 | PKR 137.82 | PKR 137.82/vial/unit | 217% above median |
| Ciproquine | Ciprofloxacin | 250 mg | Tablet | 10's | 013856 | PKR 367.99 | PKR 36.80/tablet | 46% above median |
| Ciproquine | Ciprofloxacin | 500 mg | Tablet | 10 | 019345 | PKR 647.68 | PKR 64.77/tablet | 52% above median |
| Ciproquine | Ciprofloxacin | 750 mg | Tablet | 10 | 053485 | PKR 379.54 | PKR 37.95/tablet | 5% below median |
| Ciproquine | Ciprofloxacin | 200 mg/100 mL | IV infusion | 1's | 075997 | PKR 206.34 | PKR 206.34/vial/unit | 7% below median |
| Clavox | Cefotaxime | 500 mg | Powder for injection | 1 | 021739 | PKR 170.61 | — | No comparator |
| Clavox | Cefotaxime | 1 g | Powder for injection | 1 | 021740 | PKR 300.57 | — | No comparator |
| Clavox | Cefotaxime | 250 mg | Injection | 1's | 027109 | PKR 110.89 | PKR 110.89/vial/unit | 5% above median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 250 mg + 125 mg | Tablet | 6's | 013853 | PKR 187.61 | PKR 31.27/tablet | Near median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 125 mg + 31.25 mg/5 mL | Suspension | 60ml | 013854 | PKR 172.56 | PKR 2.88/mL | 16% above median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 125 mg + 31.25 mg/5 mL | Suspension | 90ml | 013854 | PKR 222.36 | PKR 2.47/mL | Near median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 500 mg + 125 mg | Tablet | 6's | 055846 | PKR 244.36 | PKR 40.73/tablet | Near median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 875 mg + 125 mg | Tablet | 6's | 055847 | PKR 309.22 | PKR 51.54/tablet | Near median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 250 mg + 62.5 mg/5 mL | Suspension | 60ml | 057753 | PKR 271.00 | PKR 4.52/mL | 13% above median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 250 mg + 62.5 mg/5 mL | Suspension | 90ml | 057753 | PKR 361.33 | PKR 4.01/mL | Near median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 500 mg + 100 mg | Injection | 1's | 070881 | PKR 213.28 | PKR 213.28/vial/unit | 19% above median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 400 mg + 57 mg/5 mL | Suspension | 35ml | 076000 | PKR 187.61 | PKR 5.36/mL | 7% above median |
| Co-Amoxi | Amoxicillin + clavulanic acid | 400 mg + 57 mg/5 mL | Injection | 140ml | 076000 | PKR 588.64 | PKR 4.20/mL | No comparator |
| Co-Amoxi | Amoxicillin + clavulanic acid | 400 mg + 57 mg/5 mL | Suspension | 70ml | 076000 | PKR 349.75 | PKR 5.00/mL | Near median |
| Ecavir | Entecavir | 1 mg | Tablet | 30's | 055890 | PKR 35,595.95 | PKR 1,186.53/tablet | 105% above median |
| Ecavir | Entecavir | 0.5 mg | Tablet | 30's | 055990 | PKR 19,787.16 | PKR 659.57/tablet | 85% above median |
| Ecavir | Entecavir | 0.05 mg | Oral solution | 120ml | 067208 | PKR 5,444.09 | PKR 45.37/mL | No comparator |
| Infazith | Azithromycin | 500 mg | Tablet | 6's | 105444 | PKR 548.53 | PKR 91.42/tablet | 8% above median |
| Infazith | Azithromycin | 250 mg | Tablet | 6's | 105445 | PKR 299.20 | PKR 49.87/tablet | 6% above median |
| Infazith Susp | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 105446 | PKR 335.97 | PKR 22.40/mL | Near median |
| Linowin | Linezolid | 600 mg | Tablet | 12's | 057793 | PKR 5,351.95 | PKR 446.00/tablet | 13% above median |
| Linowin | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 057794 | PKR 732.86 | PKR 12.21/mL | 13% above median |
| Linowin | Linezolid | 400 mg/200 mL | Solution for infusion | 1 | 067209 | PKR 864.89 | — | No comparator |
| Linowin | Linezolid | 400 mg | IV infusion | 1 | 067209 | PKR 864.89 | — | No comparator |
| Linowin | Linezolid | 600 mg | IV infusion | 1's | 067210 | PKR 1,297.34 | PKR 1,297.34/vial/unit | 10% above median |
| Linowin | Linezolid | 200 mg/100 mL | Solution for infusion | 1 | 067211 | PKR 748.13 | — | No comparator |
| Linowin | Linezolid | 200 mg | IV infusion | 1 | 067211 | PKR 748.13 | — | No comparator |
| Mac-Mether | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 055752 | PKR 660.90 | PKR 41.31/tablet | 5% above median |
| Mac-Mether | Artemether | 80 mg | Injection | 6's | 055950 | PKR 1,189.62 | PKR 198.27/vial/unit | Near median |
| Mac-Mether | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8 | 067046 | PKR 563.04 | PKR 70.38/tablet | 10% above median |
| Mac-Mether | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6 | 067213 | PKR 703.80 | PKR 117.30/tablet | 8% above median |
| Maccillin | Ampicillin | 250 mg | Injection | 10's | 026275 | PKR 405.22 | PKR 40.52/vial/unit | 40% below median |
| Maccillin | Ampicillin | 500 mg | Injection | 10's | 026276 | PKR 619.59 | PKR 61.96/vial/unit | 27% below median |
| Macletra | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 101308 | PKR 12,331.98 | PKR 102.77/tablet | 7% above median |
| Maclinza | Daclatasvir | 30 mg | Tablet | 28's | 084772 | PKR 5,710.84 | PKR 203.96/tablet | 6% above median |
| Maclinza | Daclatasvir | 60 mg | Tablet | 28's | 084773 | PKR 9,344.27 | PKR 333.72/tablet | Near median |
| Maclusa | Sofosbuvir + Velpatasvir | 400 mg + 100 mg | Tablet | 28's | 086972 | PKR 20,176.07 | PKR 720.57/tablet | Near median |
| Mactran | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 200's | 007698 | PKR 305.81 | PKR 1.53/tablet | 45% below median |
| Mactran | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 20×10 | 007698 | PKR 331.29 | PKR 1.66/tablet | 41% below median |
| Mactran DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100's | 009880 | PKR 969.34 | PKR 9.69/tablet | Near median |
| Mactran DS | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg / 5 mL | Suspension | 50ml | 013850 | PKR 31.23 | PKR 0.62/mL | No comparator |
| Macvid | Chloroquine | 250 mg | Tablet | 50×10's | 101307 | PKR 682.72 | PKR 1.37/tablet | 13% below median |
| Maxil | Amoxicillin | 125 mg/5 mL | Suspension | 90ml | 007829 | PKR 136.66 | PKR 1.52/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.